A detailed history of Primecap Management CO transactions in Biogen Inc. stock. As of the latest transaction made, Primecap Management CO holds 16,220,716 shares of BIIB stock, worth $3.76 Billion. This represents 2.65% of its overall portfolio holdings.

Number of Shares
16,220,716
Previous 16,264,481 0.27%
Holding current value
$3.76 Billion
Previous $4.21 Billion 16.9%
% of portfolio
2.65%
Previous 3.37%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$212.02 - $267.71 $9.28 Million - $11.7 Million
-43,765 Reduced 0.27%
16,220,716 $3.5 Billion
Q4 2023

Feb 09, 2024

BUY
$222.59 - $267.94 $56.1 Million - $67.5 Million
251,915 Added 1.57%
16,264,481 $4.21 Billion
Q3 2023

Nov 13, 2023

SELL
$253.3 - $285.89 $3.37 Million - $3.81 Million
-13,310 Reduced 0.08%
16,012,566 $4.12 Billion
Q2 2023

Aug 11, 2023

BUY
$275.25 - $318.06 $6.8 Million - $7.86 Million
24,710 Added 0.15%
16,025,876 $4.56 Billion
Q1 2023

May 15, 2023

BUY
$256.56 - $292.34 $77.1 Million - $87.9 Million
300,590 Added 1.91%
16,001,166 $4.45 Billion
Q4 2022

Feb 13, 2023

SELL
$252.44 - $306.72 $10.4 Million - $12.6 Million
-41,139 Reduced 0.26%
15,700,576 $4.35 Billion
Q3 2022

Nov 14, 2022

BUY
$194.69 - $268.46 $2.96 Million - $4.08 Million
15,189 Added 0.1%
15,741,715 $4.2 Billion
Q2 2022

Aug 11, 2022

SELL
$187.54 - $223.02 $20.3 Million - $24.1 Million
-108,080 Reduced 0.68%
15,726,526 $3.21 Billion
Q1 2022

May 11, 2022

BUY
$193.77 - $244.14 $15 Million - $18.8 Million
77,201 Added 0.49%
15,834,606 $3.33 Billion
Q4 2021

Feb 11, 2022

SELL
$223.92 - $287.77 $112 Million - $144 Million
-501,510 Reduced 3.08%
15,757,405 $3.78 Billion
Q3 2021

Nov 12, 2021

SELL
$282.99 - $369.05 $56.5 Million - $73.7 Million
-199,591 Reduced 1.21%
16,258,915 $4.6 Billion
Q2 2021

Aug 10, 2021

SELL
$259.0 - $414.71 $77.6 Million - $124 Million
-299,750 Reduced 1.79%
16,458,506 $5.7 Billion
Q1 2021

May 14, 2021

BUY
$242.95 - $284.63 $227 Million - $266 Million
936,190 Added 5.92%
16,758,256 $4.69 Billion
Q4 2020

Feb 08, 2021

BUY
$236.26 - $355.63 $29.6 Million - $44.6 Million
125,362 Added 0.8%
15,822,066 $3.87 Billion
Q3 2020

Nov 13, 2020

BUY
$264.77 - $305.71 $17.1 Million - $19.8 Million
64,772 Added 0.41%
15,696,704 $4.45 Billion
Q2 2020

Aug 13, 2020

SELL
$258.66 - $342.55 $86.4 Million - $114 Million
-334,057 Reduced 2.09%
15,631,932 $4.18 Billion
Q1 2020

May 14, 2020

BUY
$268.85 - $341.04 $209 Million - $265 Million
776,508 Added 5.11%
15,965,989 $5.05 Billion
Q4 2019

Feb 14, 2020

BUY
$220.06 - $304.07 $205 Million - $283 Million
929,469 Added 6.52%
15,189,481 $4.51 Billion
Q3 2019

Nov 13, 2019

SELL
$217.44 - $243.88 $63.9 Million - $71.7 Million
-293,990 Reduced 2.02%
14,260,012 $3.32 Billion
Q2 2019

Aug 14, 2019

SELL
$219.29 - $241.72 $7.1 Million - $7.83 Million
-32,380 Reduced 0.22%
14,554,002 $3.4 Billion
Q1 2019

May 14, 2019

SELL
$216.71 - $338.96 $28.1 Million - $44 Million
-129,835 Reduced 0.88%
14,586,382 $3.45 Billion
Q4 2018

Feb 12, 2019

SELL
$278.5 - $352.75 $43.9 Million - $55.6 Million
-157,579 Reduced 1.06%
14,716,217 $4.43 Billion
Q3 2018

Nov 13, 2018

SELL
$293.51 - $383.83 $14.1 Million - $18.5 Million
-48,140 Reduced 0.32%
14,873,796 $5.26 Billion
Q2 2018

Aug 13, 2018

SELL
$257.52 - $306.91 $8.06 Million - $9.6 Million
-31,295 Reduced 0.21%
14,921,936 $4.33 Billion
Q1 2018

May 14, 2018

SELL
$260.13 - $367.91 $40.6 Million - $57.4 Million
-156,000 Reduced 1.03%
14,953,231 $4.09 Billion
Q4 2017

Feb 13, 2018

SELL
$307.64 - $344.58 $31.9 Million - $35.7 Million
-103,683 Reduced 0.68%
15,109,231 $4.81 Billion
Q3 2017

Nov 13, 2017

BUY
$281.15 - $329.69 $4.28 Billion - $5.02 Billion
15,212,914
15,212,914 $4.76 Billion

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $33.4B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Primecap Management CO Portfolio

Follow Primecap Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Primecap Management CO with notifications on news.